Comparative Pharmacology
Head-to-head clinical analysis: URECHOLINE versus VUITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: URECHOLINE versus VUITY.
URECHOLINE vs VUITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bethanechol is a synthetic choline ester that directly stimulates muscarinic acetylcholine receptors, primarily M2 and M3 subtypes, leading to increased gastrointestinal motility, bladder contraction, and other parasympathetic effects. It has minimal nicotinic activity.
VUITY (pilocarpine hydrochloride ophthalmic solution) 1.25% is a muscarinic receptor agonist. It induces miosis by contracting the iris sphincter muscle, increasing the eye's depth of focus and improving near visual acuity. It acts via the ciliary muscle to reduce the diameter of the pupil, creating a pinhole effect that enhances depth of focus.
10-50 mg orally two to four times daily; alternatively, 5 mg subcutaneously three to four times daily. Maximum oral dose: 200 mg daily.
One drop of VUITY (pilocarpine 1.25% ophthalmic solution) instilled into each eye three times daily at approximately 6-8 hour intervals.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours. Due to its short half-life, continuous or frequent dosing is required for sustained cholinergic effects.
Terminal half-life: 134 hours (range 110-170 hours). Clinical context: allows once-weekly dosing; steady-state achieved after 2-3 months.
Primarily renal excretion of unchanged drug and metabolites; approximately 50-60% excreted in urine within 24 hours, with negligible biliary or fecal elimination.
Primarily via hepatic metabolism; inactive metabolites excreted in urine (approximately 90%) and feces (approximately 10%).
Category C
Category C
Cholinergic Agonist
Cholinergic Agonist